Johnson & Johnson (NYSE:JNJ) – Leerink Swann cut their Q1 2019 earnings per share (EPS) estimates for Johnson & Johnson in a report issued on Wednesday, January 23rd. Leerink Swann analyst D. Antalffy now expects that the company will post earnings per share of $2.15 for the quarter, down from their prior estimate of $2.31. Leerink Swann also issued estimates for Johnson & Johnson’s Q2 2019 earnings at $2.37 EPS, Q3 2019 earnings at $2.18 EPS, Q4 2019 earnings at $1.90 EPS, FY2019 earnings at $8.60 EPS, Q3 2020 earnings at $2.42 EPS, FY2020 earnings at $9.30 EPS, FY2021 earnings at $10.00 EPS, FY2022 earnings at $10.95 EPS and FY2023 earnings at $11.95 EPS.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, January 22nd. The company reported $1.97 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.95 by $0.02. The company had revenue of $20.39 billion for the quarter, compared to the consensus estimate of $20.27 billion. Johnson & Johnson had a net margin of 18.75% and a return on equity of 35.09%. The firm’s quarterly revenue was up 1.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.74 EPS.
A number of other equities research analysts also recently issued reports on JNJ. Credit Suisse Group set a $149.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Sunday, October 14th. HC Wainwright reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Wednesday, October 17th. Wells Fargo & Co reissued an “outperform” rating and set a $160.00 price objective (up previously from $155.00) on shares of Johnson & Johnson in a research note on Wednesday, October 17th. Raymond James raised their price target on Johnson & Johnson from $144.00 to $149.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 17th. Finally, Citigroup raised their price target on Johnson & Johnson from $137.00 to $148.00 and gave the stock a “neutral” rating in a research note on Monday, October 22nd. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have assigned a buy rating to the company’s stock. Johnson & Johnson currently has a consensus rating of “Hold” and a consensus price target of $139.90.
NYSE JNJ opened at $128.80 on Thursday. Johnson & Johnson has a 52 week low of $118.62 and a 52 week high of $148.99. The stock has a market cap of $345.56 billion, a price-to-earnings ratio of 15.75, a price-to-earnings-growth ratio of 1.92 and a beta of 0.72. The company has a current ratio of 1.72, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46.
A number of hedge funds have recently bought and sold shares of the business. Horan Securities Inc. lifted its holdings in shares of Johnson & Johnson by 122.3% in the 4th quarter. Horan Securities Inc. now owns 438 shares of the company’s stock valued at $56,000 after purchasing an additional 241 shares during the last quarter. Stuart Chaussee & Associates Inc. increased its position in Johnson & Johnson by 20.7% during the 4th quarter. Stuart Chaussee & Associates Inc. now owns 466 shares of the company’s stock worth $60,000 after purchasing an additional 80 shares during the period. FNY Investment Advisers LLC increased its position in Johnson & Johnson by 594.4% during the 4th quarter. FNY Investment Advisers LLC now owns 500 shares of the company’s stock worth $64,000 after purchasing an additional 428 shares during the period. Selective Wealth Management acquired a new position in Johnson & Johnson during the 3rd quarter worth approximately $105,000. Finally, CKW Financial Group grew its holdings in shares of Johnson & Johnson by 18.8% in the 4th quarter. CKW Financial Group now owns 810 shares of the company’s stock worth $105,000 after acquiring an additional 128 shares during the period. 66.23% of the stock is owned by institutional investors.
In related news, EVP Michael E. Sneed sold 30,943 shares of Johnson & Johnson stock in a transaction that occurred on Friday, November 23rd. The stock was sold at an average price of $142.46, for a total transaction of $4,408,139.78. Following the transaction, the executive vice president now owns 70,817 shares in the company, valued at $10,088,589.82. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Charles Prince acquired 2,000 shares of Johnson & Johnson stock in a transaction that occurred on Friday, December 14th. The shares were bought at an average price of $134.37 per share, for a total transaction of $268,740.00. Following the transaction, the director now owns 28,520 shares of the company’s stock, valued at approximately $3,832,232.40. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 514,187 shares of company stock worth $74,951,528. 0.22% of the stock is owned by corporate insiders.
Johnson & Johnson announced that its board has initiated a share repurchase plan on Monday, December 17th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the company to reacquire up to 1.5% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s board believes its shares are undervalued.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 12th. Investors of record on Tuesday, February 26th will be issued a dividend of $0.90 per share. This represents a $3.60 annualized dividend and a yield of 2.80%. The ex-dividend date of this dividend is Monday, February 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 44.01%.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
Read More: Intrinsic Value
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.